18614071. Fetal Microchimeric Cells and EVs for Regenerative Medicine in Women's Health simplified abstract (Board of Regents, The University of Texas System)

Fetal Microchimeric Cells and EVs for Regenerative Medicine in Women's Health

Organization Name

Board of Regents, The University of Texas System

Inventor(s)

Ramkumar Menon of Galveston TX (US)

Ananth Kumar Kammala of Galveston TX (US)

Elizabeth Bonney of Galveston TX (US)

Fetal Microchimeric Cells and EVs for Regenerative Medicine in Women's Health - A simplified explanation of the abstract

This abstract first appeared for US patent application 18614071 titled 'Fetal Microchimeric Cells and EVs for Regenerative Medicine in Women's Health

Simplified Explanation

This patent application discusses methods and compositions for determining the risk of maternal cardiovascular disease caused by an infection by measuring fetal microchimeric cells in a biological sample and using a machine learning algorithm to calculate the risk.

• Obtaining a biological sample from a subject at risk of maternal cardiovascular disease.
• Measuring fetal microchimeric cells in the sample.
• Using a machine learning algorithm to calculate the risk of cardiovascular disease based on the presence of these cells.

Key Features and Innovation

• Utilizes fetal microchimeric cells to assess the risk of maternal cardiovascular disease.
• Incorporates machine learning algorithms for risk calculation.
• Provides a non-invasive method for predicting cardiovascular disease risk in pregnant women.

Potential Applications

• Predicting maternal cardiovascular disease risk in pregnant women.
• Monitoring the impact of infections on maternal health during pregnancy.
• Personalized healthcare for pregnant women based on risk assessment.

Problems Solved

• Lack of efficient methods for predicting maternal cardiovascular disease risk.
• Limited understanding of the relationship between infections and maternal health during pregnancy.
• Need for non-invasive diagnostic tools for assessing cardiovascular disease risk in pregnant women.

Benefits

• Early detection of maternal cardiovascular disease risk.
• Tailored healthcare interventions for pregnant women.
• Improved maternal and fetal health outcomes.

Commercial Applications

Cardiovascular Disease Risk Assessment in Pregnant Women: Market Implications and Potential Commercial Uses

Questions about the Technology

What are the potential long-term implications of using fetal microchimeric cells for predicting maternal cardiovascular disease risk?

Using fetal microchimeric cells for risk assessment could lead to personalized healthcare interventions for pregnant women, potentially improving maternal and fetal health outcomes in the long term.

How accurate is the machine learning algorithm in predicting cardiovascular disease risk based on fetal microchimeric cells?

The accuracy of the machine learning algorithm in predicting cardiovascular disease risk based on fetal microchimeric cells would depend on the quality and quantity of data used for training the algorithm.

Original Abstract Submitted

Provided herein are methods and compositions for determining an increased risk of maternal cardiovascular disease caused by an infection comprising: obtaining, or having obtained, a biological sample from a subject at risk of, of having had a pre-term birth; measuring fetal microchimeric cells or fetal extracellular vesicles in the biological sample; and using a machine learning algorithm calculating a risk of cardiovascular disease based on the an increase or a decrease in fetal microchimeric cells in the biological sample when compared to a maternal sample from a subject that does not have an infection.